首页 | 本学科首页   官方微博 | 高级检索  
检索        

新型冠状病毒肺炎患者抗病毒治疗的药学监护:基于试行第七版诊疗方案
引用本文:陈丽坪,吴燕,金澄滔,吴圣洁.新型冠状病毒肺炎患者抗病毒治疗的药学监护:基于试行第七版诊疗方案[J].中国现代应用药学,2020,37(5):549-554.
作者姓名:陈丽坪  吴燕  金澄滔  吴圣洁
作者单位:浙江大学医学院附属邵逸夫医院,浙江大学医学院附属邵逸夫医院,浙江大学医学院附属邵逸夫医院,浙江大学医学院附属邵逸夫医院
基金项目:浙江省医药卫生科技项目青年人才项目,浙江省药学会医院药学专项资助项目
摘    要:合并基础疾病的新型冠状病毒肺炎患者用药较多,为尽可能减少药物间的相互作用、提升药物治疗效果、减少患者药物不良反应发生率,本文对国家卫生健康委员会《新型冠状病毒肺炎诊疗方案(试行第七版)》纳入的抗病毒药物与其他治疗药物之间可能存在的药物相互作用进行阐述,并提供药学监护建议,以期为临床合理用药提供建议。

关 键 词:新型冠状病毒肺炎  基础疾病  药物相互作用  药学监护
收稿时间:2020/2/24 0:00:00
修稿时间:2020/2/27 0:00:00

Pharmaceutical Care of Antiviral Drugs in COVID-19 Patients: Based on Diagnosis and Treatment Scheme(Trial Version 7)
CHEN Liping,WU Yan,JIN Chengtao and WU Shengjie.Pharmaceutical Care of Antiviral Drugs in COVID-19 Patients: Based on Diagnosis and Treatment Scheme(Trial Version 7)[J].The Chinese Journal of Modern Applied Pharmacy,2020,37(5):549-554.
Authors:CHEN Liping  WU Yan  JIN Chengtao and WU Shengjie
Institution:Sir Run Run Shaw''s Hospital, School of Medicine, Zhejiang University,Sir Run Run Shaw''s Hospital, School of Medicine, Zhejiang University,Sir Run Run Shaw''s Hospital, School of Medicine, Zhejiang University,Sir Run Run Shaw''s Hospital, School of Medicine, Zhejiang University
Abstract:The patients with both novel coronavirus pneumonia (COVID-19) infection and basic diseases have to take multiple medications. In order to reduce the drug interaction, improve the effect of medical treatment, and reduce the incidence of adverse drug reactions in patients, the drug interactions between antiviral drugs included in the National Health and Health Commission''s diagnosis and treatment scheme (Trial version 7) and other therapeutic drugs are elaborated in this article. Based on this, we also offer a proposal on pharmaceutical care, hoping to provide medication advice for the rational clinical treatment.
Keywords:COVID-19  basic diseases  drug-drug interaction  pharmaceutical care
本文献已被 维普 等数据库收录!
点击此处可从《中国现代应用药学》浏览原始摘要信息
点击此处可从《中国现代应用药学》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号